VEGF inhibitors for the treatment of neovascular age-related macular degeneration

Expert Opinion on Investigational Drugs

Volumn 18, Issue 5, 2009, Pages 637-646

  Barakat, Mark Rami ^a   Kaiser, P K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Age related macular degeneration; VEGF

Indexed keywords

AFLIBERCEPT; AG 013958; AGN 211745; AL 39324; BEVACIZUMAB; BEVASIRANIB; IMATINIB; PAZOPANIB; PEGAPTANIB; PROTEIN TYROSINE KINASE INHIBITOR; RANIBIZUMAB; RAPAMYCIN; SIRNA 027; SUNITINIB; TG 100801; TG 101095; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR; VATALANIB;

ANEMIA; ARTHRALGIA; BLOOD PRESSURE; COLON CANCER; DERMATITIS; DIABETIC RETINOPATHY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TARGETING; DRUG TOLERABILITY; ELECTROLYTE BLOOD LEVEL; ENDOPHTHALMITIS; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INFECTION; INTERSTITIAL PNEUMONIA; LIPID BLOOD LEVEL; METASTASIS; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; OFF LABEL DRUG USE; PERIORBITAL EDEMA; PERIPHERAL EDEMA; QUALITY OF LIFE; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RNA INTERFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SKIN TOXICITY; SUBRETINAL NEOVASCULARIZATION; THROMBOCYTOPENIA; TRAUMATIC LENS INJURY; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; VISUAL IMPAIRMENT;

ANIMALS; APTAMERS, NUCLEOTIDE; HUMANS; MACULAR DEGENERATION; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67649622340     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780902855316     Document Type: Review

References (73)

1. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-572
2. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417-1436 (Pubitemid 32963246)
3. Ruiter DJ, Schlingemann RO, Westphal JR, et al. Angiogenesis in wound healing and tumor metastasis. Behring Inst Mitt 1993;92:258-272
4. Ferrara N, Chen H, Davis-Smyth T, et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 1998;4:336-340
5. Yano K, Brown LF, Detmar M. Control of hair-growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest 2001;107:409-417 (Pubitemid 32167987)
6. Kiefer FN, Neysari S, Humar R, et al. Hypertension and angiogenesis. Curr Pharm Des 2003;9:1733-1744
7. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002;29:10-14
8. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364 (Pubitemid 26272076)
9. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endotherlial growth factor is a secreted angiogneic mitogen. Science 1989;246:1306-1309
10. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-442
11. Olofsson B, Korpelainen E, Pepper MS, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 1998;95:11709-11714
12. Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001;7:186-191
13. Wells JA, Murthy R, Chibber R, et al. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol 1996;80:363-366 (Pubitemid 26113591)
14. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37:1929-1934 (Pubitemid 26324159)
15. Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997;81:154-162 (Pubitemid 27092496)
16. Ruckman J, Green LS, Beeson J, et al. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998;273:20556-20567 (Pubitemid 28377626)
17. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002;22:143-152 (Pubitemid 36125089)
18. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816 •• Demonstrated utility of pegaptanib in neovascular AMD.
19. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120:338-346
20. Kim KJ, Li B, Houck K, et al. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992;7:53-64
21. Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999;293:865-881 (Pubitemid 29527672)
22. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005;112:1048-1053
23. Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999;27:536-544
24. Jackson TL, Antcliff RJ, Hillenkamp J, Marshall J. Human retinal molecular weight exclusion limit and estimate of species variation. Invest Ophthalmol Vis Sci 2003;44:2141-2146 (Pubitemid 36520310)
25. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46:726-733
26. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431 •• Demonstrated usefulness of ranibizumab in AMD with minimally classic or occult CNV. (Pubitemid 44511557)
27. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444 •• Demonstrated usefulness of ranibizumab in AMD with predominantly classic CNV. (Pubitemid 44511558)
28. Lucentis® (ranibizumab injection) prescribing information. South San Francisco, California: Genentech, Inc.; 2008
29. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008;145:239-248 •• Explored alternative ranibizumab dosing regimen in neovascular AMD.
30. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacisumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-1047
31. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335 •• Demonstrated treatment response of neovascular AMD to intravitreal bevacizumab. (Pubitemid 41073112)
32. Hudson PJ, Souriau C. Engineered antibodies. Nat Med 2003;9:129-134 (Pubitemid 36098274)
33. Sawada O, Kawamura H, Kakinoki M, et al. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol 2007;125(10):1363-1366
34. Krohne TU, Eter N, Holz FG, et al. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008;146(4):508-512
35. Zhu Q, Ziemssen F, Henke-Fahle S, et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 1755;115(10):1750-1755
36. Comparison of Age-Related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial. [ClinicalTrials.gov identifier: NCT00593450]. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/ NCT00593450 [Last accessed 17 Dec 2008]
37. Konner J, Dupont J. Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity. Clin Colorectal Cancer 2004;4:S81-5 (Pubitemid 39440148)
38. Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med 2003;9:47-52
39. VEGF Trap-Eye Final Phase 2 Results in Age-related Macular Degeneration Presented at 2008 Retina Society Meeting. Regeneron.com. Available from: http://newsroom.regeneron.com/phoenix.zhtml?c=214847&p=irol- newsArticle&ID=1202860&highlight [Last accessed 17 Dec 2008]
40. Reich SJ, Fosnot J, Kuroki A, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003;9:210-216
41. Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3.[see comment]. Nature 2008;452(7187):591-597
42. Shen J, Samul R, Silva RL, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2006;13(3):225-234
43. Brucker A. Small interfering RNA (CAND5) for the treatment of subfoveal choroidal neovascularization due to age-related macular degeneration. Combined Retina Society/Gonin Society Meeting; 2006 Oct 15-20; Cape Town
44. Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (COBALT). [ClinicalTrials.gov identifier: NCT00499590]. ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov/ ct2/show/NCT00499590 [Last accessed 17 Dec 2008]
45. A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) [ClinicalTrials.gov identifier: NCT00363714]. ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov/ ct2/show/NCT00363714 [Last accessed 17 Dec 2008]
46. A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration [ClinicalTrials.gov identifier: NCT00395057]. ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov/ ct2/show/NCT00395057 [Last accessed 17 Dec 2008]
47. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. [see comment]. N Engl J Med 2002;347(7):472-480 (Pubitemid 34879334)
48. Nishida T, Shirao K, Sawaki A, et al. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). Int J Clin Oncol 2008;13(3):244-251 (Pubitemid 351871892)
49. George S. Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor. Curr Oncol Rep 2007;9(4):323-327 (Pubitemid 47045167)
50. Maier P, Unsoeld AS, Junnker B, et al. Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice. Graefes Arch Clin Exp Ophthalmol 2005;243(6):593-600
51. Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD) (ADVANCE) [ClinicalTrials.gov identifier: NCT00138632]. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT00138632 [Last accessed 17 Dec 2008]
52. A Study to Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD [ClinicalTrials.gov identifier: NCT00612456]. ClinicalTrials.gov. Available from: http://clinicaltrials. gov/ct2/show/NCT00612456 [Last accessed 17 Dec 2008]
53. Chen ZZ, Mak C, Renick J, et al. A dual VEGFR/JAK2 kinase inhibitor suitable for topical delivery inhibits choroid neovascularization in mice [abstract no. E-1469]. Invest Ophthalmol Vis Sci 2007;48(5). Available from: http://abstracts.iovs.org/cgi/content/abstract/48/5/1469 [Last accessed 17 Dec 2008]
54. Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD [ClinicalTrials.gov identifier: NCT00509548]. ClinicalTrials.gov. Available from: http://clinicaltrials. gov/ct2/show/ NCT00509548 [Last accessed 17 Dec 2008]
55. A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration [ClinicalTrials.gov identifier: NCT00090532]. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT00090532 [Last accessed 17 Dec 2008]
56. Bingaman DP, Gu X, Landers RA, et al. AL-39324 is more potent and efficacious against ocular NV vs. other RTKi's [abstract no. E-1747]. Invest Ophthalmol Vis Sci 2007;48(5). Available from: http://abstracts.iovs.org/cgi/ content/abstract/48/5/1747 [Last accessed 17 Dec 2008]
57. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transpl Proc 2003;35(3 Suppl):7S-14S (Pubitemid 36547910)
58. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8(2):128-135
59. Kleinman DM, Kim DD, Nivaggioli T, et al. Sirolimus inhibits VEGF-induced microvascular hyperpermeability [abstract no. E-1422]. Invest Ophthalmol Vis Sci 2007;48(5). Available from: http://abstracts.iovs.org/cgi/content/abstract/ 48/5/1422 [Last accessed 17 Dec 2008]
60. Dejneka NS, Kuroki AM, Fosnot J, et al. Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis 2004;10:964-972
61. Merkel S, Mogilevskaja N, Mengel M, et al. Side effects of sirolimus. Transpl Proc 2006;38(3):714-715
62. Morath C, Schwenger V, Ksoll-Rudek D, et al. Four cases of sirolimus-associated interstitial pneumonitis: identification of risk factors. Transpl Proc 2007;39(1):99-102
63. Toso C, Meeberg GA, Bigam DL, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 2007;83(9):1162-1168
64. Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration [ClinicalTrials.gov identifier: NCT00712491]. ClinicalTrials.gov. Available from: http://clinicaltrials. gov/ct2/show/NCT00712491 [Last accessed 17 Dec 2008]
65. Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration (EMERALD) [ClinicalTrials.gov identifier: NCT00766337]. ClinicalTrials.gov. Available from: http://clinicaltrials. gov/ct2/show/NCT00766337 [Last accessed 17 Dec 2008]
66. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583 (Pubitemid 46452533)
67. Lalwani G. All About PrONTO: Study Yielded Good Results in AMD With Treatment Guided by OCT. www.retinatoday.com. http://www.retinatoday.com/ Html%20Pages/0507/0507-cme.html [Last accessed 18/12/08] •• Explored alternative, OCT-guided ranibizumab dosing regimen in neovascular AMD.
68. Guttman C. Intravitreal ranibizumab therapy safe, well tolerated, study shows.Available from: www.modernmedicine.com. Available from: http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/ Intravitreal-ranibizumab-therapy-safe-well-tolerat/ArticleStandard/Article/ detail/566351 [Last accessed 29 Dec 2008] •• Extension trial exploring utility of ranibizumab administered at clinician's discretion for neovascular AMD.
69. Steinbrook R. The price of sight - ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006;355(14):1409-1412 (Pubitemid 44511554)
70. Raftery J, Clegg A, Jone J, et al. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modeling cost effectiveness. Br J Ophthalmol 2007;91:1244-1246 (Pubitemid 47344908)
71. Fletcher EC, Lade RJ, Adewoyin T, Chong NV. Computerized model of cost-utility analysis for treatment of age-related macular degeneration. Ophthalmology 2008;115:2192-2198
72. Swaroop A, Branham KE, Chen W, Abecasis G. Genetic susceptibility to age-related macular degeneration: a paradigm for dissecting complex disease traits. Hum Mol Genet 2007;16(Rev2):R174-82
73. Klein ML, Francis PJ, Rosner B, et al. CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmology 2008;115(6):1019-1025